Effects of Canagliflozin on Abnormal Liver Function Tests in Patients of Type 2 Diabetes with Non-Alcoholic Fatty Liver Disease.

Conclusions: Canagliflozin controls HbA1c and reduce weight in type 2 diabetes. It also significantly improves LFT in co-morbid NAFLD. PMID: 31324087 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31324087?dopt=Abstract

Source: Journal of the Association of Physicians of India - July 22, 2019 Category: General Medicine Tags: J Assoc Physicians India Source Type: research